The FDA Oncologic Drugs Advisory Committee and the Cellular, Tissue and Gene Therapies Advisory Committee will jointly review talimogene laherparepvec for the treatment of patients with injectable regionally or distantly metastatic melanoma at a meeting April 29.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
